A new trading day began on November 20, 2023, with Organon & Co. (NYSE: OGN) stock priced at $11.23, down -1.06% from the previous day of trading. During the day, the shares moved up to $11.30 and dropped to $11.105 before settling in for the closing price of $11.31. OGN’s price has ranged from $10.90 to $32.43 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -9.29% over the past five years. Meanwhile, its annual earnings per share averaged -18.54%. With a float of $255.33 million, this company’s outstanding shares have now reached $255.61 million.
Let’s look at the performance matrix of the company that is accounted for 10000 employees. In terms of profitability, gross margin is +63.07, operating margin of +27.84, and the pretax margin is +18.17.
Organon & Co. (OGN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Organon & Co. is 0.11%, while institutional ownership is 79.13%.
Organon & Co. (OGN) Performance Highlights and Predictions
In its latest quarterly report, released on 9/29/2023, the company reported earnings of $0.87 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of +14.85. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.00% during the next five years compared to -12.77% drop over the previous five years of trading.
Organon & Co. (NYSE: OGN) Trading Performance Indicators
Here are Organon & Co.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.47. Likewise, its price to free cash flow for the trailing twelve months is 6.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.29, a number that is poised to hit 0.79 in the next quarter and is forecasted to reach 4.26 in one year’s time.
Technical Analysis of Organon & Co. (OGN)
Organon & Co. (NYSE: OGN) saw its 5-day average volume 3.83 million, a positive change from its year-to-date volume of 2.81 million. As of the previous 9 days, the stock’s Stochastic %D was 14.13%. Additionally, its Average True Range was 0.56.
During the past 100 days, Organon & Co.’s (OGN) raw stochastic average was set at 2.16%, which indicates a significant decrease from 7.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.92% in the past 14 days, which was higher than the 40.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.66, while its 200-day Moving Average is $20.75. Nevertheless, the first resistance level for the watch stands at $11.29 in the near term. At $11.39, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.49. If the price goes on to break the first support level at $11.10, it is likely to go to the next support level at $11.00. Assuming the price breaks the second support level, the third support level stands at $10.90.
Organon & Co. (NYSE: OGN) Key Stats
With a market capitalization of 2.86 billion, the company has a total of 255,606K Shares Outstanding. Currently, annual sales are 6,174 M while annual income is 917,000 K. The company’s previous quarter sales were 1,519 M while its latest quarter income was 58,000 K.